EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Real-World Data on Empagliflozin and Dapagliflozin Use in Patients with HEART Failure: The RED–HEART Study

Umut Kocabas, Isil Ergin, Veysel Yavuz, Cihan Altın, Mehmet Kaplan, Gülsüm Meral Yılmaz Öztekin, Mustafa Doğduş, Selda Murat, Bektaş Murat, Tarık Kıvrak, Dilay Karabulut, Ersin Kaya und 13 weitere

ESC Heart Failure · 01.02.2025 · 12 (1) · 434-446

DOI: 10.1002/ehf2.15049 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift ESC Heart Failure, online erschienen am 28.09.2024. Verfasst von Umut Kocabas und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Başkent University İzmir Hospital, İzmir, Türkiye. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Heart Failure, Sodium-Glucose Transporter 2 Inhibitors, Glucosides. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We aimed to determine the use of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting.

Methods

Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023.

Results

The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19–101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06–3.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27–9.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16–6.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72–13.20; P < 0.001), the use of angiotensin receptor–neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39–7.01; P < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49–2.75; P < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18–2.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30–2.29; P < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45–0.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37–0.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48–0.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49–0.91; P = 0.010) were independently associated with the non-use of SGLT2is.

Conclusions

The RED–HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsHeart FailureSodium-Glucose Transporter 2 InhibitorsGlucosidesStroke VolumeHumansMaleFemaleAgedMiddle AgedCross-Sectional StudiesAged, 80 and overAdultYoung AdultRetrospective Studies

Stichwörter der Autor:innen

guidelineheart failuresodium–glucose cotransporter 2 inhibitors

Substanzen

Benzhydryl CompoundsdapagliflozinSodium-Glucose Transporter 2 InhibitorsGlucosidesempagliflozin

Autor:innen und Institutionen

  • Department of Cardiology, Başkent University İzmir Hospital, İzmir, Türkiye.
  • Department of Public Health, Faculty of Medicine, Ege University, İzmir, Türkiye.
  • Department of Cardiology, Akhisar Mustafa Kirazoglu State Hospital, Manisa, Türkiye.
  • Department of Cardiology, İzmir University of Economics, Faculty of Medicine, Medical Point Hospital, İzmir, Türkiye.
  • Department of Cardiology, Gaziantep University Medical School, Gaziantep, Türkiye.
  • Department of Cardiology, University of Health Sciences, Antalya Training and Research Hospital, Antalya, Türkiye.

Zitieren

APA

Kocabas, U., Ergin, I., Yavuz, V., Altın, C., Kaplan, M., Yılmaz Öztekin, G. M., Doğduş, M., Murat, S., Murat, B., Kıvrak, T., Karabulut, D., Kaya, E., Özdemir, İ. H., Yıldız, C., Salkın, F. Ö., Özçalık, E., Polatkan, Ş. G., Çakan, F., Şen, T., …, & Türk, U. Ö. (2025). Real-World Data on Empagliflozin and Dapagliflozin Use in Patients with HEART Failure: The RED–HEART Study. ESC Heart Failure, 12(1), 434-446. https://doi.org/10.1002/ehf2.15049

Vancouver

Kocabas U, Ergin I, Yavuz V, Altın C, Kaplan M, Yılmaz Öztekin GM, et al. Real-World Data on Empagliflozin and Dapagliflozin Use in Patients with HEART Failure: The RED–HEART Study. ESC Heart Failure. 2025;12(1):434-446. doi:10.1002/ehf2.15049

BibTeX
@article{Kocabas2025,
  author = {Kocabas, Umut and Ergin, Isil and Yavuz, Veysel and Altın, Cihan and Kaplan, Mehmet and Yılmaz Öztekin, Gülsüm Meral and Doğduş, Mustafa and Murat, Selda and Murat, Bektaş and Kıvrak, Tarık and Karabulut, Dilay and Kaya, Ersin and Özdemir, İbrahim Halil and Yıldız, Cennet and Salkın, Fatma Özge and Özçalık, Emre and Polatkan, Şeyda Günay and Çakan, Fahri and Şen, Taner and Karabulut, Umut and Çakal, Sinem and Oflar, Ersan and Sinan, Ümit Yaşar and Yenerçağ, Mustafa and Türk, Uğur Önsel},
  title = {Real-World Data on Empagliflozin and Dapagliflozin Use in Patients with HEART Failure: The RED–HEART Study},
  journal = {ESC Heart Failure},
  year = {2025},
  volume = {12},
  number = {1},
  pages = {434--446},
  doi = {10.1002/ehf2.15049}
}
Kostenlos starten →